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Abstract
Background: In acne, several studies report a poor adherence to treatments. We evaluate, in a real-life setting conditions,
the impact of compliance to physician’s instructions, recommendations and adherence to the treatments on clinical
outcome in patients with mild to moderate acne in an observational, non-interventional prospective study carried out in
72 Dermatologic Services in Spain (ACTUO Trial).
Methods: Six-hundred-forty-three subjects were enrolled and 566 patients (88 %) completed the 3 study visits. Study
aimed to evaluate the impact of adherence (assessed with ECOB scale) on clinical outcome, as well as how the use of
specific adjuvant treatments (facial cleansing, emollient, moisturizing and lenitive specific topical products) influences
treatment’s adherence and acne severity (0–5 points score). Recommendation of specific adjuvant skin barrier repair
products was made in 85.2 %.
Results: Overall, clinical improvement was observed throughout follow-up visits with an increased proportion of patients
who reported reductions of ≥50 % on the total number of lesions (2 months: 25.2 %; 3 months: 57.6 %) and reductions
of severity scores (2.5, 2.0 and 1.3 at 1, 2 and 3 months after treatment, respectively). Adherence to treatment was
associated with a significant reduction on severity grading, a lower number of lesions and a higher proportion of patients
with ≥50 % improvement.
Conclusions: Good adherence to medication plus adherence to adjuvants was significantly associated with a higher
clinical improvement unlike those that despite adherence with medication had a low adherence to adjuvants. A good
adherence to adjuvant treatment was
associated with improved adherence and better treatment outcomes in mild to moderate acne patients.
(ISRCTN Registry: ISRCTN14257026).
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Background
Acne is a common skin chronic disease that very often
requires prolonged treatments [1]. With a chronic course
[2] and an episodic pattern of presentation [3], Acne
vulgaris lesions occur mainly in exposed areas like the
face and the presternal region. The effect of the scarring
may be notable and the functional, social and emotional
impact on the patient’s quality of life may be significant
[4, 5]. Adherence to doctor prescriptions has a major
impact on treatment outcome [6]. Several studies con-
ducted over the past few years suggest that adherence to
acne medications is particularly low [3, 7] and has been
associated with inadequate response to therapy [8], es-
pecially when both topical and systemic treatments are
prescribed to the same patient [9]. The treatment plan
and the choice of specific active ingredients should take
into account not only the individual characteristics of
the patient and/or the disease but also their preferences
and expectations with treatment as well as questions
of convenience [10].The adverse effects of the various
therapies available should also be borne in mind in order
to increase adherence to the physician’s instructions
and recommendations, thus promoting what are known
as health-related behaviours [7]. Specific systemic and
topical acne treatments are very often associated with
local side effect such as dry, burning and itching sensa-
tions [7] hence poor tolerability further worsens compli-
ance [11].,Based on the evidence and clinical experience
obtained with topical treatments and their possible irritant
effects [12], adjuvant skin barrier repair therapies such as
specific emulsion and detergent products, hydrating and
emollients are often prescribed in order to reduce these
side effects, all in search of improving adherence to thera-
peutic strategies [13, 14]. Other factors such as a good
and efficient physician-patient relationship are also crucial
for improving adherence to therapeutic strategy [15]
since this interaction includes specific roles and motiva-
tions [16] that might be essential to the healing of many
patients, particularly so for patients with chronic disease
or disease having a negative impact on quality of life and
self-esteem such as acne [17]. Adherence with acne
therapies has been evaluated mainly in subjects irre-
spective to grading severity of the condition (from mild
to severe forms) [8, 18] but, so far, few data are avail-
able regarding this conduct in patients with mild to
moderate forms. We evaluated in a real-life setting
condition the impact of adherence to dermatologist in-
structions and recommendations and adherence to the
treatments x(specific anti acne treatments and adju-
vant therapies) on the clinical outcome in patients with
mild to moderate acne. The participating physicians of
the ACTUO trial were practicing experienced Spanish
dermatologists working in hospital outpatient derma-
tology services.
Methods
ACTUO was a multicenter, prospective, observational,
epidemiological study of patients with mild to moderate
acne treated at 72 dermatology services throughout Spain
between October 2011 and November 2012. All study ma-
terials were evaluated and approved by a Clinical Research
Ethics Committee before the study start. Approval (Ethics
Committee of “Centro Medico Teknon” Barcelona Spain)
was obtained August 1, 2011.
a) Subjects
A total of 643 subjects with mild to moderate acne, after
they provided written informed consent, were enrolled in
the study. Eligibility criteria were men and women with
mild to moderate acne vulgaris eligible for a specific acne
treatment (topical retinoid agents or antiseptics and/or
systemic antibiotics) willing to participate in the study. The
study was conducted at three visits carried out in a period
of three months (V1: baseline, and two follow-up visits: V2
and V3). In all 3 visits, data on acne severity was recorded
on the Case Report Form (CRF) by the dermatologist using
the global ranking system of the FDA [19] (0: no lesions, 4:
severe) and the total number of acne lesions. Acne severity
was also evaluated by the patient. In addition, adher-
ence to anti-acne treatments and adjuvant therapies
was also assessed trough study.
b) Primary outcome
The main objective of this analysis was to evaluate the
impact of adherence to the treatments on the clinical out-
come in patients with mild to moderate acne. A secondary
outcome was to evaluate the impact of the use of specific
adjuvant treatments (facial cleansing products, emollient
moisturizing and lenitive specific topical cream products
containing mainly rhamnosoft as emollient and antiflam-
matory agent) on adherence level and entity of the clinical
outcome obtained. Acne severity was assessed at each visit
with a 5-point score system (from 0 to 4), absolute count of
lesions and percentage of patient reaching a ≥50 % re-
duction in lesion numbers. Adherence to treatment
was evaluated at visit 2 and visit 3 by means of vali-
dated 4-item questionnaire (ECOB) with a dichotom-
ous classification: good adherence (ECOB score = 4)
and poor adherence (ECOB <4). Poor adherence to
treatment was defined as a different to expected an-
swer on the ECOB questionnaire. The four questions
of ECOB were according to Pawin et al. [20].
The degree of adherence to the adjuvant measures pre-
scribed by the doctor (application of cleansers and moistur-
izers for facial skin care) was assessed using the data
provided by the patients attending all three study visits. It
was considered that patients who followed all their doctor’s
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instructions and recommendations in at least three of the
four assessments showed compliance with the medical
advice. The effects of adherence to adjuvant treatment on
the doctor’s and patient’s final assessments of acne severity
was compared in patients "without /practically without
lesions" (FDA scores = 0–1) and patients "with lesions"
(FDA scores ≥ 2–4). The ACTUO study has evaluated also
the impact of acne and acne treatments on quality of life
evaluated by means of Cardiff Acne Disability Index [21]
(CADI) and Dermatology Life Quality Index (DLQI) [22].
However these data would be presented elsewhere.
c) Statistical methods
The FDA ratings made by the physician and patient after
three months were grouped into two categories: presence
of lesions (FDA ≥2-4), or absence or near absence of lesions
(FDA= 0–1). Using the parameters severity and total num-
ber of lesions, improvement was assessed by classifying
patients into two groups based on the reduction of acne
severity (≥50 % improvement vs. improvement <50 %) and
the percentages of reduction of comedones and papules/
pustules. Statistical analysis was performed using the
statistical software SPSS ver.19. Continuous variables
were expressed as mean (SD). Categorical binary variables
were expressed as proportions (%). The Mann–Whitney,
Wilcoxon and the chi-square tests were used for infer-
ence statistical analysis tests. A multivariate logistics
regression analysis was performed in order to assess the
correlation between improvement of acne severity score,
percentage of patients with 50 % or more in acne lesion
number reduction, and the following variable: demo-
graphic data, adherence to specific treatments and to
adjuvant treatments.
Results
Table 1 gives information about patients’ characteristics at
the time of enrollment. A total of 643 cases were enrolled.
A total of 566 patients (88 %) completed the 3-visit study.
Data are presented as per protocol analysis. At baseline,
adjuvant products were prescribed in 83.8 % of the pa-
tients. The application frequency was 1.3/day. Prescription
for specific adjuvant products was made for 85.2 % of the
patients. Severity of acne assessed by the physician was
2.5 ± 0.6 and mean number of comedones was 18.9 ± 2.
Severity acne score was significantly (p < 0.001) reduced in
comparison with baseline after 1 month (2.0 ± 0.8) and
after 3 months (1.3 ± 0.9). At the end of study period
patients scoring 0 (complete cure of acne) were 17 %. In
general, significant reductions in the severity scores vis-à-
vis the baseline visit were observed in both doctor's and
patients’ assessment (2.1 ± 0.9 at one month and 1.4 ± 0.9
at three months; p < 0.001). Figure 1 shows the evolution
of acne severity score in the population as a whole.
Percentage of patients showing at least 50 % of lesion
reduction was 25.2 % at visit 2 and 57.6 % at visit 3.
According to the ECOB scores, good adherence to treat-
ment was documented in 50.0 % of the patients at visit 2
and in 66.3 % at visit 3. Good adherence to treatment was
associated with a significant (p < 0.05) acne improvement
in comparison with poor adherence group at both control
visits. At visit 3 acne severity score was 1.19 ± 0.8 in
patients with good adherence to adjuvants vs. 1.4 ± 0.9 in
poor adherence group. Good adherence to specific acne
treatments (facial cleansers) was documented in 83.6 % at
visit 2 and in 89.9 % at visit 3. At the end of study, patients
with good adherence to treatment presented a significant
improvement of acne both in term of acne severity score
(1.2 vs. 1.7; p = 0.001) and regarding the proportion of
patients whom reduction of lesions was ≥50 % (60.9 % vs.
32.8 %; p < 0.001) when compared to those with poor
adherence (Fig. 2). In patients for whom the dermatologist
had prescribed adjuvant therapies, a good adherence to
this treatment was documented in 36.2 %. Adherence to
adjuvant treatment improves acne thus it was associated
with a significant reduction of score grading severity at visit
3 (1.2 vs. 1.4; P = 0.002), with a higher percentage of
reduction of average lesions number vs. baseline
(50.8 % vs. 43.7 %; p = 0.015) and with more patients
obtaining a ≥50 % reduction in acne lesions’ number
(65.9 % vs. 51.5 %; p = 0.003) in comparison with the low
adherence group (Fig. 2). Adherence to adjuvant treatments
was associated with a greater proportion of patients with a
complete cure of acne (defined as no or very few acne
lesions) at the final visit in comparison with poor-adherers
(66.5 % vs. 52.6 %; p = 0.004). In particular, good adherence
to adjuvant treatments improved the adherence to topical
retinoid therapy therefore influencing clinical improvement
of acne showing a higher proportion patients with adher-
ence to treatment in adherers to adjuvants when compared
to non-adherers (85.5 % vs. 70.7 %; p < 0.001). In addition,
in patients with a good adherence toadjuvants were signifi-
cantly more frequently considered with an ≥50 % improve-
ment on clinical outcome in comparison with those that
did not adhere to adjuvants (65.9 % vs. 51.5 %; p = 0.003).
Multiple logistic regression analysis was performed
to identify factors influencing clinical improvement of
acne. Adherence to specific treatments, adherence to
adjuvant treatments and good adherence to treatment
are significantly (p = 0.001) correlated with clinical im-
provement of acne. In accordance with previous studies,
sex (women vs. men) and the fact to be accompanied
(by parents/tutor or relative) or not at the medical visit
are also independent factors affecting improvement
clinical outcome of acne. Other analysis allowed observ-
ing an association between the patient’s assessment of
quality of life based on the DLQI scale and the adher-
ence to adjuvant treatment since rates of improvement
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on QoL were lower in non-compliers (43 % vs. 56.1 %,
p = 0.007).
Discussion
Low adherence to treatments is still a relevant problem in
the treatment of mild to moderate acne [23]. The definition
of strategies to improve adherence with both pharmaco-
logical and behavioural treatment remains a major chal-
lenge. Suboptimal medication adherence is one of the
major reasons for treatment failure in subject with acne
vulgaris [24]. Our findings reveal that dermatologists in
Spain frequently prescribe specific adjuvant treatment for
acne. They recommend the use of specific products
including non-comedogenic soaps and moisturizers in over
80 % of acne patients. The synergy between the effects of
drug treatment and adjuvant products can improve comfort
during the various stages of treatment and can encourage
patients to continue the application of the products. Adher-
ence to adjuvant treatment was associated not only with a
2.4-fold increase in the probability of adherence to pharma-
cological treatment, but also with a significant reduction in
acne severity, in the number of lesions as assessed by both
Table 1 Sociodemographic data and acne severity at baseline visit
n mean (SD) n (%)
Gender Male 635 – 240 (37.8 %)
Female 395 (62.2 %)
Age 617 21.3 (7.2)
Study level Primary school 632 – 24 (3.8 %)
Secondary school 151 (23.9 %)
Vocational training (school) 51 (8.1 %)
Pre-university 188 (29.7 %)
Vocational training (technical college) 30 (4.7 %)
First cycle university studies 41 (6.5 %)
Second cycle university studies 146 (23.1 %)
Others 1 (0.2 %)
Physician’s acne
evaluation
Without lesions 640 2.47 (0.64) –
Practically without lesions 32 (5.0 %)
Mild 298 (46.6 %)
Moderate 290 (45.3 %)
Severe 20 (3.1 %)
Patient’s acne
evaluation
Without lesions 594 2.10 (0.85) 16 (2.7 %)
Practically without lesions 126 (21.2 %)
Mild 245 (41.2 %)
Moderate 195 (32.8 %)
Severe 12 (2.0 %)
Lesion locationa Facial 637 – 622 (97.6 %)
Back 212 (33.3 %)
Shoulders 81 (12.7 %)
Presternal area 73 (11.5 %)
Others 2 (0.3 %)
Total number of lesionsa
(Percentages of 568
patients with lesions)
Comedones 546 18.9 (20.4) 532 (93.7 %)
Papules/pustules 551 11.4 (10.2) 545 (96.0 %)





specific facial care products)
No 640 – 104 (16.3 %)
Yes 536 (83.8 %)
aNon-exclusive categories
N number of patients, SD standard deviation; % = Percentage
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the treating physician and the patient, and a higher per-
centage of patients whose severity improved by 50 % or
more. In the ACTUO study low adherence to treatment
was found in 50 % of the patients (at 1 month) and this re-
sult is in line with previous published data. Low adherence
to adjuvant treatments was observed in up to 63.8 % of
subjects after 3 months. In addition we have to consider
that these data derived from a per protocol analysis, not
including 12.4 % of patients not attending to control visits
which therefore could be considered as”non-complier” by
definition. In line with previous experiences [3], we have
observed that adherence to pharmacological treatment is a
key factor for the improvement of acne both in terms
of reduction of severity grading, number of lesions and
percentage of patients obtaining at least a 50 % acne im-
provement. Good adherence to adjuvant treatments also
improves clinical evolution of acne with a greater reduction
of severity of grading and number of lesions and with a
significant greater percentage of patients obtaining a 50 %
or more improvement of acne in comparison with patients
with poor adherence to adjuvant treatments. Furthermore,
patients with good adherence with drug and those with
adherence to adjuvant treatments presented the highest
percentage of patients with improvement of acne lesions
≥50 %. In addition, in the present study it was shown that
adherence to adjuvant products is the second most import-
ant factor (just after adherence to drug treatment) influen-
cing the degree of acne improvement. A good adherence to
adjuvant treatment is associated with an improved adher-
ence to acne treatments and with a better treatment out-
come in mild to moderate acne patients. Some limitations
should be taken in account in evaluating the results of
our study. In particular the evaluation of compliance was
based on self-reporting questionnaire. This approach how-
ever was used in other studies assessing the same outcome
and the ECOB questionnaire is considered a validated
tool [3, 18]. On the other hand, we believe that the sample
size and the study design adopted, quite close to “real life”
conditions of acne treatment strategies, could be consi-
dered as aspects increasing the external validity and the
generalization of the observed results of the ACTUO.
Conclusions
The ACTUO observational study results confirm that
adherence to pharmacological treatment and adjuvant ther-
apies are both key factors of acne improvement in terms of
reduction of severity, number of lesions and percentage of
patients with at least a 50 % acne improvement. In addition,
Fig. 2 Patients with Acne improvement ≥50 % and regarding adherence to pharmacological and compliance with adjuvant treatments
Fig. 1 Evolution of acne severity score in the ACTUO study population
as a whole
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adherence to adjuvant treatment with specific cleansers and
moisturizers for patients with acne is the second most
important factor in achieving symptom improvement, after
completion of drug treatment. Good adherence to adjuvant
treatment is associated with a 2.2-fold increase in the prob-
ability of adherence to topical pharmacological treatment
and with significant reductions in the severity and number
of acne lesions.
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